A new delivery method muscling its way into the RNA space

In focus with: Sarah Boyce, CEO and president of Avidity Biosciences

Avidity’s vision: Experts have heralded RNA-based therapeutics for their potential to treat rare and challenging genetically-driven diseases failed by conventional therapies. The field has seen a surge of interest following the success of the mRNA vaccines developed during the pandemic, driving a market that may reach $18 billion by 2028. Avidity is looking to make RNA treatments a possibility for conditions previously out of reach due to drug delivery challenges.